NEOLA.ST logo
NEOLA.ST(NEOLA.ST)
$0.48—Stale · unknown old
9/28/26

Neola Medical AB (publ) (NEOLA.ST)

Monday
6:43 AM
ThesisConcerns over competitive threats and the lack of revenue generation are dampening investor sentiment despite potential growth opportunities.

Revenue Outlook

★ Analysts see FY2027 revenue reaching $13M — +9.9% growth in a single year.

What Moves the Stock

  1. 01Regulatory approvals for new medical devices
  2. 02Partnership announcements with healthcare providers
  3. 03Clinical trial results demonstrating efficacy of products
  4. 04Market expansion into new European countries
  5. 05Sales of respiratory medical devices - 100%
  6. 06Telehealth integration in respiratory care
  7. 07Increased focus on patient-centric medical devices
FY2025 Snapshot
Revenue
$0.00
EPS
$-0.14
1Y Return
-77.3%

NEOLA.ST Chart

0.40.81.11.51.90.47NEOLA.ST Daily0.47May '26Jun '26Aug '26Sep '26

My Notes

  • "The market is cautious as we navigate a challenging landscape with emerging technologies."
  • Moat: Neola Medical's proprietary technology provides a temporary competitive edge, but it is vulnerable to rapid innovation from larger players.
  • growth - Investors looking for innovative medical technology with potential for high returns.
  • Low - The company is currently debt-free, so rising interest rates do not impact financing costs…
  • Watch on earnings: Regulatory approval timelines for new devices, Clinical trial success rates, Sales growth in European markets.

One Sentence Summary:

Neola Medical AB (publ): the story is balanced — regulatory approvals for new medical devices.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.